A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Inclusion Criteria

• •Body mass index (BMI) 18 to 32 kg/m2;
• •Forced expiratory volume in one second (FEV1) ≥80% of predicted for race, age, sex, and height;
• •FEV1/FVC (forced vital capacity) ratio ≥70%;
• •Smokers are defined as those currently smoking at least 10 cigarettes/day for at least 12 months with a positive urinary cotinine result and with no past (within 5 years) or present history of intrinsic lung disease (e.g. asthma, chronic obstructive pulmonary disease \[COPD\], chronic bronchitis, or other relevant conditions);
• •Non-smokers are defined as those who never smoked or were exposed to less than 1 pack year within at least 12 months and with a negative urinary cotinine result.